http://www.orcid.org/0000-0003-3863-9689



Practical Applications of New Approach Methodologies (NAM) in Chemical Safety Assessment: Applying US EPA Tools/Approaches in Practice

Generalized Read-across (GenRA) – Data driven systematic readacross approaches

**Grace Patlewicz** 

Center for Computational Toxicology and Exposure, US-EPA, RTP, NC

The views expressed in this presentation are those of the author and do not necessarily reflect the views or policies of the U.S. EPA

10/23/2020 Happy Mole Day!











- Where does read-across fit in an integrated testing and assessment approach (IATA)
- What is read-across?
- Read-across tools and frameworks?
- How is read-across evolving? A GenRA perspective
- GenRA workflow
- Example using GenRA
- Ongoing work
- Summary remarks
- Acknowledgements



- Integrated Approaches to Testing and Assessment (IATA)
- "A tiered approach to data gathering, testing, and assessment that integrates different types of data (including physicochemical and other chemical properties as well as *in vitro* and *in vivo* toxicity data). When combined with estimates of exposure in an appropriate manner, the IATA provides predictions of risk."

#### **General framework of an IATA**



Problem formulation. Definition of the regulatory need (e.g. hazard identification, hazard characterisation, safety assessment etc.) and the information/parameters that are relevant to satisfy the need, including consideration of existing constraints and, if applicable, consideration of the level of certainty required.


Gather and evaluate existing information (in vivo, in vitro, in silico (e.g. (Q)SAR), read across and chemical category data).

Make a weight of evidence assessment or apply predefined decision criteria (e.g. ITS, STS).

Available information provides sound conclusive evidence for the specific regulatory need

If available information does not provide sufficient evidence consider what additional information from non-testing, non-animal testing methods and, as a last resort, from animal methods would be needed to generate sufficient evidence.

Make a weight of evidence assessment or apply predefined decision criteria (i.e. ITS, STS).







"Analogue approach" refers to grouping based on a very limited number of chemicals (e.g. target substance + source substance)


"Category approach" is used when grouping is based on a more extensive range of analogues (e.g. 3 or more members)

A chemical category is a group of chemicals whose physicochemical and human health and/or environmental toxicological and/or environmental fate properties are likely to be similar or follow a regular pattern as a result of structural similarity (or other similarity characteristics).


#### Definition




- <u>Read-across</u> describes the method of filling a data gap whereby a chemical with existing data values is used to make a prediction for a 'similar' chemical.
- A <u>target chemical</u> is a chemical which has a data gap that needs to be filled i.e. the subject of the read-across.
- A <u>source analogue</u> is a chemical that has been identified as an appropriate chemical for use in a read-across based on similarity to the target chemical and existence of relevant data.



- Reliable data
- O Missing data




### **Selected read-across tools**



SEPA United States Environmental Protection Agency

# **Read-across workflow**






## A harmonized hybrid read-across workflow



Journal Cover

Image



Contents lists available at ScienceDirect

#### **Computational Toxicology**

journal homepage: www.elsevier.com

# Navigating through the minefield of read-across frameworks: A commentary perspective

Grace Patlewicz<sup>a,</sup> \*, Mark T.D. Cronin<sup>b</sup>, George Helman<sup>a, c</sup>, Jason C. Lambert<sup>d</sup>, Lucina E. Lizarraga<sup>d</sup>, Imran Shah<sup>a</sup>


<sup>a</sup> National Center for Computational Toxicology (NCCT), Office of Research and Development, US Environmental Protection Agency (US EPA), 109 TW Alexander Dr, Research Triangle Park (RTP), NC 27711, USA

<sup>b</sup> School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK

- <sup>c</sup> Oak Ridge Institute for Science and Education (ORISE), 1299 Bethel Valley Road, Oak Ridge, TN 37830, USA
- <sup>d</sup> National Center for Evaluation Assessment (NCEA), US Environmental Protection Agency (US EPA), 26 West Martin Luther King Dr, Cincinnati, OH 45268, USA

#### A harmonized hybrid read-across workflow





Where do other new approach data streams fit? E.g. mechanistic data from ToxCast

How should we transition to data-driven approaches? moving away from subjective expert driven assessments.

What about characterizing the uncertainty of the predictions made?

# GenRA (Generalized Read-Across)



- Predicting toxicity as a similarity-weighted activity of nearest neighbors based on chemistry and bioactivity descriptors (Shah et al, 2016)
- •Generalized version of the Chemical-Biological Read-Across (CBRA) developed by Low et al (2013)
- •Goal: To establish an objective performance baseline for readacross and quantify the uncertainty in the predictions made

$$y_{i}^{\beta,\alpha} = \frac{\sum_{j=1}^{k} s_{ij}^{\alpha} x_{j}^{\beta}}{\sum_{j=1}^{k} s_{ij}^{\alpha}}$$


Jaccard similarity:

$$s_{ij} = \frac{\sum_{l} (x_{il} \wedge x_{jl})}{\sum_{l} (x_{il} \vee x_{jl})}$$

 $\alpha \Box \{ chm, bio, bc \}$   $\beta \Box \{ bio, tox \}$   $y_i = predicted activity of chemical(c_i)$   $x_j^{\beta} = activity of c_j \text{ in } \beta$   $s_{ij}^{\alpha} = Jacccard similarity between x_i^{\alpha}, x_j^{\alpha}$ k = up to k nearest neighbours

# Read-across workflow in GenRA v1.0






# GenRA tool web-based tool







.≎.FP∆

GenRA
















Step Two: Data Gap Analysis & Generate Data Matrix											
Neighbors by: Chem: Morgan Fgrprts 💙 Filter by: invivo data 💙 🚯	Summary Data Gap Ana	alysis 🚯	Group: ToxRef 💙	By: Tox Fingerprint 💙	Generate Data Matrix	0					
<ul> <li>How data poor is my target and</li> </ul>				0,0:000 1,4.000000000000000000000000000000000000	44.00 1-0000000000000000000000000000000000						
what data exists for the source		bio ber	CHR:Abdominal Cavity								
analogues identified	p,p'-DDD	ダ/ ダ/ ダ/ ダ/ <mark>42 <mark>714</mark> 10 0</mark>	CHR:Adrenal Gland								
<ul> <li>Do they address the data gaps of</li> </ul>	1,4-Dichlorobenzene	7 714 4 345	CHR:Artery (General)								
interest for the target chemical?	4-Chloroaniline	6 <mark>714</mark> 6 83 17 0 7 <mark>168</mark>	CHR:Auditory Startle Re								
	o,p'-DDT	37 <b>726</b> 12 <b>177</b>	CHR:Bile duct								
p,p'-DDD	Dicofol	40 818 17 345 9 271 5 168	CHR:Blood								
0,p'-DDT	1-Chloro-4-nitrobenzene	10 674 5 167	CHR:Blood vessel								
	Monuron	12 <b>714</b> 7 168	CHR:Body Weight								
	Chlorophacinone	51 234 19 95 9 232 8 180	CHR:Bone								
Monuron Dicofol			CHR:Bone Marrow								
			CHR:Brain								
of Analogs 10 1-Chloro-4-nitro 4,4'-Dichlorodip Next			CHR:Bronchus			•					



What is the consistency and concordance across my source analogues? Should I deselect analogues from consideration from the entire set of predictions? Should I consider subcategorizing the analogues selected?

Toxicity data represented as binary outcomes – red (positive), blue (negative), grey (no data)









- Database underpinning GenRA v1.0: ToxRefDB v1
  - Different study types and effects within them are predicted e.g. chronic\_liver is annotated as CHR\_liver
  - Negative results assume that if a particular guideline study was conducted but the effects were not reported than a chemical would be negative for that particular effect for that type of guideline study
  - Positive results min dose at which toxicity effects are observed in a study
- Prediction: Similarity weighted activity
- Performance is categorized by the AUC of the ROC
  - The significance was empirically estimated by constructing a null distribution by permuting the toxicity values 100 times and calculating the fraction of times the AUC was more extreme than what would be observed by chance (this is reported as the p-value).



- Ability to export the predictions into a tsv/excel file
- Output is shown mirrors the data matrix view but doses replace the colour coding

_					
role	target	analog	analog	analog	analog
preferred	p,p'-DDD	1,4-Dichlo	4-Chloroa	4-Chloroa	o,p'-DDT
dsstox_sid	DTXSID402	DTXSID102	DTXSID902	DTXSID402	DTXSID602
molecular	320.03	147	127.57	164.03	354.48
similarity	1	0.391304	0.310345	0.3	0.295455
CHR:Abdo	GenRA Ne	no_effect	no_effect	no_effect	no_data
CHR:Adrer	GenRA Pos	600mg/kg	no_effect	18mg/kg/c	no_data
CHR:Arter	GenRA Ne	no_effect	no_effect	no_effect	no_data
CHR:Audit	GenRA Ne	no_effect	no_effect	no_effect	no_data
CHR:Bile d	GenRA Ne	no_effect	no_effect	no_effect	no_data
CHR:Blooc	GenRA Ne	150mg/kg,	no_effect	3mg/kg/da	no_data
CHR:Blooc	GenRA Ne	no_effect	no_effect	no_effect	no_data
CHR·Rody	GenRA Por	300mg/kg	375mg/kg	no effect	no data



#### • Output can be analyzed in different ways

role	target	analog	
preferred name	p,p'-DDD	1,4-Dichlorobenzene	
dsstox_sid	DTXSID4020373	DTXSID1020431	
molecular weight	320.03	147	
similarity	1	0.391304348	
CHR:Abdominal Cavity	GenRA Neg Act=0 (0) AUC=0 p=1	no_effect	
CHR:Adrenal Gland	GenRA Pos Act=1 (0.546) AUC=0 p=0.975	600mg/kg/day	
CHR:Artery (General)	GenRA Neg Act=0 (0) AUC=0 p=1	no_effect	
CHR:Auditory Startle Reflex Habituation	GenRA Neg Act=0 (0) AUC=0 p=1	no_effect	
CHR:Bile duct	GenRA Neg Act=0 (0) AUC=0 p=1	no_effect	
CHR:Blood	GenRA Neg Act=0 (0.386) AUC=0 p=0.95	150mg/kg/day	
CHR:Blood vessel	GenRA Neg Act=0 (0) AUC=0 p=1	no_effect	
CHR:Body Weight	GenRA Pos Act=1 (0.832) AUC=0 p=0.8	300mg/kg/day	
CHR:Bone	GenRA Neg Act=0 (0) AUC=0 p=1	no_effect	
CHR:Bone Marrow	GenRA Neg Act=0 (0.168) AUC=0 p=0.85	no_effect	
CHR:Brain	GenRA Neg Act=0 (0) AUC=0 p=1	no_effect	
CHR:Bronchus	GenRA Neg Act=0 (0) AUC=0 p=1	no_effect	



- Rank order positive results based on AUC and p values
- Look at the distribution of positive vs negatives predictions
- Explore what effects are being identified for the source analogues – consider identifying the underlying data for source analogues (elsewhere on the Dashboard) – is there a critical effect that is driving the toxicity that should be compared with the target chemical predictions?
- . .
- Depends on the decision context and the level of uncertainty that can be tolerated.

# **GenRA – Ongoing refinements**

 Consideration of other information to define and refine the analogue selection & evaluation – e.g. physicochemical similarity, metabolic similarity, reactivity similarity, mechanistic similarity (transcriptomics similarity, phenotypic profiling similarity) al Protection

- Quantitative predictions of toxicity e.g. LOAEL, LD50
- Read-across to predict other *in vitro* endpoints to supplement *in vitro-in vivo* extrapolations

## Summary remarks



- Read-across is an important component of an IATA
- Read-across acceptance for regulatory purposes remains an issue mainly due to the difficulties of addressing residual uncertainties and the fact that read-across is a subjective expert driven assessment.
- GenRA is an attempt to move towards an objective read-across approach where uncertainties and performance can be quantified.
- GenRA v1.0 establishes a baseline in performance. The approach relies on chemical descriptors to predict binary toxicity values but work is ongoing to characterize other contexts of similarity (e.g. mechanistic, reactivity, metabolism) and quantify their contribution in predicting *in vivo* toxicity outcomes.
- GenRA v1.0 exists as an app within the Dashboard to facilitate a workflow approach to make read-across predictions. A python package (genra-py) will be released soon to facilitate batch processing using user specific datasets.



- Imran Shah co-collaborator
- George Helman former student
- Tony Williams Project Owner for the Dashboard





## **Grace Patlewicz**

CCTE, US EPA Office of Research and Development, patlewicz.grace@epa.gov

ORCID: https://orcid.org/0000-0003-3863-9689